Mesoblast to sell 5,742,510 American Depositary Shares through IPO

Bookrunners JPMorgan and Credit Suisse will assist with offering

By Devika Patel

Knoxville, Tenn., Nov. 6 – Mesoblast Ltd. will sell 5,742,510 American Depositary Shares in its initial public offering with a greenshoe of 861,376 additional ADSs, according to a Form F-1/A filed Monday with the Securities and Exchange Commission. The company has registered up to $79,907,021 of underlying ordinary stock for the deal.

Each ADS represents five ordinary shares.

JPMorgan and Credit Suisse are the bookrunners. Maxim Group LLC and Ladenburg Thalmann are the co-managers.

Proceeds will be used for commercial manufacturing, clinical trials, general and administrative expenses, working capital and other general corporate purposes.

The regenerative medicine technology company is based in Melbourne, Australia. The company has applied to list the ADSs on the Nasdaq under the symbol “MESO.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.